Analyst ratings, especially those initiating coverage with a positive outlook, can significantly influence investor sentiment and stock prices. The Market Outperform rating and the $12 price target set by JMP Securities for Werewolf Therapeutics suggest a bullish outlook for the stock, likely leading to increased investor interest and potentially a rise in stock price in the short term.